HPV E2、E5致癌机制及相关疫苗研究进展

崔湘杰; 史荔; 陶玉芬

doi:10.16462/j.cnki.zhjbkz.2024.01.015

HPV E2、E5致癌机制及相关疫苗研究进展

doi: 10.16462/j.cnki.zhjbkz.2024.01.015

中国医学科学院医学生物学研究所史荔实验室，昆明 650118

基金项目:

云南省重大科技专项计划 202002AA100009

中国医学科学院医学与健康科技创新工程项目 2021-I2M-1-004

详细信息

通讯作者:
陶玉芬，E-mail：taoyufen@imbcams.com.cn

中图分类号: R737.33
计量
- 文章访问数: 217
- HTML全文浏览量: 185
- PDF下载量: 35
- 被引次数: 0
出版历程
- 收稿日期: 2023-06-21
- 修回日期: 2023-08-31
- 网络出版日期: 2024-02-05
- 刊出日期: 2024-01-10

Research progress in the study of HPV E2, E5 oncogenic mechanism and related vaccine

Shi Li Laboratory, Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China

Funds:

Major Science and Technology Projects of Yunnan Provincial 202002AA100009

Chinese Academy of Medical Sciences Innovation Fund for Medical Science 2021-I2M-1-004

More Information

Corresponding author: TAO Yufen, E-mail: taoyufen@imbcams.com.cn

摘要

摘要: 宫颈癌是影响女性的常见恶性肿瘤之一，其中高危型HPV的持续感染是导致宫颈癌的主要病因。在宫颈癌的发生发展过程中，除了HPV E6、E7与宫颈癌病变有主要的关系外，其他一些早期蛋白如E2、E5也发挥了重要的作用。如E2可以启动并维持病毒的复制，而E5可以与E6、E7癌蛋白合作，促进感染细胞增殖。本研究仅就HPV E2、E5在宫颈癌发生发展中的机制以及相关的治疗性疫苗研究进展进行综述。
- 宫颈癌 /
- 人乳头瘤病毒 /
- E2蛋白 /
- E5蛋白 /
- 疫苗
Abstract: Cervical cancer is one of the common malignancies affecting women worldwide, of which persistent infection with high-risk human papillomavirus (HPV) is the main cause. In the occurrence and development of cervical cancer, in addition to HPV E6, E7 and cervical cancer lesions have a major relationship, some other early proteins such as E2 and E5 also play an essential role. For example, E2 can initiate and maintain viral replication, and E5 can cooperate with E6 and E7 oncoproteins to promote proliferation of infected cells. In this paper, we aim to review the current research progress on the mechanism of HPV E2 and E5 proteins in the development of cervical cancer and the progress of research on E2 and E5 related therapeutic vaccines.
- Cervical cancer /
- Human papillomavirus /
- E2 protein /
- E5 protein /
- Vaccine

HTML全文

参考文献(29)

[1]	Harden ME, Munger K. Human papillomavirus molecular biology[J]. Mutat Res Mutat Res, 2017, 772: 3-12. DOI: 10.1016/j.mrrev.2016.07.002.
[2]	Mo YC, Ma JB, Zhang HT, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives[J]. Front Cell Infect Microbiol, 2022, 12: 909223. DOI: 10.3389/fcimb.2022.909223.
[3]	Ren SL, Gaykalova DA, Guo T, et al. HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers[J]. Oncogene, 2020, 39 (40): 6327-6339. DOI: 10.1038/s41388-020-01431-8.
[4]	Eberhardt CS, Kissick HT, Patel MR, et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer[J]. Nature, 2021, 597(7875): 279-284. DOI: 10.1038/s41586-021-03862-z.
[5]	Dai SY, Yao YT, Yan ZL, et al. The association of human papillomavirus type 16 E2 variations with cervical cancer in a Han Chinese population[J]. Infect Genet Evol, 2018, 64: 241-248. DOI: 10.1016/j.meegid.2018.07.002.
[6]	Chojnacki M, Melendy T. The HPV E2 transcriptional transactivation protein stimulates cellular DNA polymerase epsilon[J]. Viruses, 2018, 10(6): 321. DOI: 10.3390/v10060321.
[7]	Bergvall M, Melendy T, Archambault J. The E1 proteins[J]. Virology, 2013, 445(1-2): 35-56. DOI: 10.1016/j.virol.2013.07.020.
[8]	Hegde RS. The papillomavirus E2 proteins: structure, function, and biology[J]. Annu Rev Biophys Biomol Struct, 2002, 31: 343-360. DOI: 10.1146/annurev.biophys.31.100901.142129.
[9]	Zhou LY, Qiu QZ, Zhou Q, et al. Long-read sequencing unveils high-resolution HPV integration and its oncogenic progression in cervical cancer[J]. Nat Commun, 2022, 13 (1): 2563. DOI: 10.1038/s41467-022-30190-1.
[10]	Ramírez-Salazar E, Centeno F, Nieto K, et al. HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation[J]. Virol J, 2011, 8: 247. DOI: 10.1186/1743-422X-8-247.
[11]	Singh N, Senapati S, Bose K. Insights into the mechanism of human papillomavirus E2-induced procaspase-8 activation and cell death[J]. Sci Rep, 2016, 6: 21408. DOI: 10.1038/srep21408.
[12]	DiMaio D, Petti LM. The E5 proteins[J]. Virology, 2013, 445 (1-2): 99-114. DOI: 10.1016/j.virol.2013.05.006.
[13]	Bravo IG, Alonso A. Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth[J]. J Virol, 2004, 78 (24): 13613-13626. DOI: 10.1128/JVI.78.24.13613-13626.2004.
[14]	de Freitas AC, de Oliveira THA, Barros MR, et al. hrHPV E5 oncoprotein: immune evasion and related immunotherapies[J]. J Exp Clin Cancer Res, 2017, 36 (1): 71. DOI: 10.1186/s13046-017-0541-1.
[15]	Lorenzon L, Mazzetta F, Venuti A, et al. In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix[J]. J Clin Virol, 2011, 52 (2): 79-83. DOI: 10.1016/j.jcv.2011.06.007.
[16]	Ilahi NE, Bhatti A. Impact of HPV E5 on viral life cycle via EGFR signaling[J]. Microb Pathog, 2020, 139: 103923. DOI: 10.1016/j.micpath.2019.103923.
[17]	Venuti A, Paolini F, Nasir L, et al. Papillomavirus E5: the smallest oncoprotein with many functions[J]. Mol Cancer, 2011, 10: 140. DOI: 10.1186/1476-4598-10-140.
[18]	Maufort JP, Shai A, Pitot HC, et al. A role for HPV16 E5 in cervical carcinogenesis[J]. Cancer Res, 2010, 70 (7): 2924-2931. DOI: 10.1158/0008-5472.CAN-09-3436.
[19]	Hochmann J, Parietti F, Martínez J, et al. Human papillomavirus type 18 E5 oncoprotein cooperates with E6 and E7 in promoting cell viability and invasion and in modulating the cellular redox state[J]. Mem Inst Oswaldo Cruz, 2020, 115: e190405. DOI: 10.1590/0074-02760190405.
[20]	García-Hernández E, González-Sánchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine[J]. Cancer Gene Ther, 2006, 13(6): 592-597. DOI: 10.1038/sj.cgt.7700937.
[21]	Rosales R, López-Contreras M, Rosales C, et al. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine[J]. Hum Gene Ther, 2014, 25(12): 1035-1049. DOI: 10.1089/hum.2014.024.
[22]	Ragonnaud E, Andersson AC, Mariya S, et al. Therapeutic vaccine against primate papillomavirus infections of the cervix[J]. J Immunother, 2017, 40(2): 51-61. DOI: 10.1097/CJI.0000000000000153.
[23]	Boilesen DR, Neckermann P, Willert T, et al. Efficacy and synergy with cisplatin of an adenovirus vectored therapeutic E1E2E6E7 vaccine against HPV genome-positive C3 cancers in mice[J]. Cancer Immunol Res, 2023, 11 (2): 261-275. DOI: 10.1158/2326-6066.CIR-22-0174.
[24]	Diniz MO, Lasaro MO, Ertl HC, et al. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D[J]. Clin Vaccine Immunol, 2010, 17 (10): 1576-1583. DOI: 10.1128/CVI.00264-10.
[25]	Diniz MO, Ferreira LC. Enhanced anti-tumor effect of a gene Gun-delivered DNA vaccine encoding the human papillomavirus type 16 oncoproteins genetically fused to the herpes simplex virus glycoprotein D[J]. Braz J Med Biol Res, 2011, 44 (5): 421-427. DOI: 10.1590/S0100-879X2011007500039.
[26]	Liao SJ, Deng DR, Zeng D, et al. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo[J]. J Huazhong Univ Sci Technol Med Sci, 2013, 33 (5): 735-742. DOI: 10.1007/s11596-013-1189-5.
[27]	Liao SJ, Zhang WN, Hu XJ, et al. A novel "priming-boosting" strategy for immune interventions in cervical cancer[J]. Mol Immunol, 2015, 64 (2): 295-305. DOI: 10.1016/j.molimm.2014.12.007.
[28]	Wang Q, Li QF, Zhang J, et al. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model[J]. Vaccine, 2022, 40 (52): 7693-7702. DOI: 10.1016/j.vaccine.2022.10.069.
[29]	Hancock G, Blight J, Lopez-Camacho C, et al. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins[J]. Sci Rep, 2019, 9 (1): 18713. DOI: 10.1038/s41598-019-55014-z.